Treatment options for pityriasis rubra pilaris including biologic agents: a retrospective analysis from an academic medical center.

Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents: A Retrospective Analysis From an Academic Medical Center Pityriasis rubra pilaris (PRP) is characterized by hyperkeratotic papules, palmoplantar keratoderma, and widespread erythema with islands of sparing. Treatment is challenging, and a standard therapeutic protocol does not exist. Given the paucity of available therapeutic data, we assessed the clinical presentation of PRP and clinical response (CR) to therapy at 2 teaching hospitals in Boston, Massachusetts. In addition, we aimed to determine the role of systemic and biologic agents.

[1]  T. Tsai,et al.  Pityriasis rubra pilaris with polyarthritis treated with adalimumab. , 2013, Journal of the American Academy of Dermatology.

[2]  Youwen Zhou,et al.  Type I Pityriasis Rubra Pilaris: Upregulation of Tumor Necrosis Factor α and Response to Adalimumab Therapy , 2010, Journal of cutaneous medicine and surgery.

[3]  U. Wollina,et al.  Pityriasis rubra pilaris – a retrospective single center analysis over eight years , 2010, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  S. Garcovich,et al.  Treatment of refractory adult‐onset pityriasis rubra pilaris with TNF‐alpha antagonists: a case series , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  B. Zelger,et al.  Infliximab monotherapy as first-line treatment for adult-onset pityriasis rubra pilaris: case report and review of the literature on biologic therapy. , 2008, Journal of the American Academy of Dermatology.